noted that although rare adverse events such as nausea, facial flushing, and redness at the injection site were noted, sermorelin appears to have a very favorable safety profile [5]
Corresponding Author: Carol Lim, MD, MPH, Department of Psychiatry, Massachusetts General Hospital, 151 Merrimac St, 4th Floor, Boston, MA 02114 ([email protected])
No direct opioid receptor binding by DSIP was ever demonstrated
Results vary, but typically, 810 sessions at weekly intervals show noticeable skin brightening and improved glow
Additionally, the medication led to decreases in various factors associated with an increased risk of heart and metabolic diseases, including blood pressure, visceral adiposity, and circulating triglycerides
Patients should follow the advice of their bariatric team regarding their particular monitoring plan